GlassScriptPhysician profile
Samatha Chandupatla
NPI 1114918356
$2,819.58
in general payments reported to CMS, 2019-2025
20 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $349 · 2021: $406 · 2022: $650 · 2023: $401 · 2024: $310 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,085.78 | 2019-2024 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $402.86 | 2021-2023 | Krystexxa |
| Amgen INC. | $392.32 | 2022-2025 | Krystexxa, Tavneos, Parsabiv |
| Mallinckrodt Enterprises LLC | $264.11 | 2019 | |
| Fresenius USA Marketing, INC. | $106.73 | 2019-2020 | |
| Vifor Pharma, INC. | $100.06 | 2019-2023 | Veltassa |
| Glaxosmithkline, LLC. | $80.62 | 2021-2024 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $65.87 | 2019-2023 | Jynarque |
| Daiichi Sankyo INC. | $54.34 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $29.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.48 | 2024 | Jardiance |
| Cook Medical LLC | $28.42 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $28.18 | 2024 | |
| Opko Pharmaceuticals, LLC | $25.18 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.81 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $23.21 | 2021 | |
| Boston Scientific Corporation | $22.80 | 2022 | |
| Calliditas Therapeutics US INC. | $21.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.79 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samatha Chandupatla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.